Asked by: Janet Daby (Labour - Lewisham East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with NHS England and the National Institute for Health and Care Excellence on access to new treatments for sickle cell disease and beta thalassaemia.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department regularly discusses a range of issues with colleagues in NHS England and the National Institute for Health and Care Excellence (NICE) related to patient access to effective new treatments. NICE appraises all newly licensed medicines and aims to publish draft guidance around the time of licensing wherever possible. NICE works closely with the Medicines and Healthcare products Regulatory Agency and NHS England to ensure that there is a joined-up, timely approach to supporting access to new treatments for National Health Service patients.
NICE is currently appraising exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia and sickle cell disease, and expects to publish final guidance in March and April 2024 respectively.
Nov. 16 2023
Source Page: MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemiaFound: MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent
Mentions:
1: Janet Daby (Lab - Lewisham East) questions on the future of the NHS for sickle cell patients. - Speech Link
2: Preet Kaur Gill (LAB - Birmingham, Edgbaston) about sickle cell disease and equality in the NHS, and the hon. - Speech Link
Sep. 21 2023
Source Page: Q4 KPI Screening Data (1 January to 31 March)Found: cell and thalassaemia (SCT) screening for whom a screening result is available at the day of reportST2
Sep. 21 2023
Source Page: Q4 KPI Screening Data (1 January to 31 March)Found: infant physical examination (screening programme) SCT Sickle cell and thalassaemia (screening programme
Aug. 17 2023
Source Page: Sickle cell and thalassaemia (SCT) screening: programme overviewFound: Sickle cell and thalassaemia (SCT) screening: programme overview
Aug. 17 2023
Source Page: 2021/22 Sickle cell and thalassaemia screening (SCT) screening reportFound: 2021/22 Sickle cell and thalassaemia screening (SCT) screening report
Aug. 17 2023
Source Page: 2021/22 Sickle cell and thalassaemia screening (SCT) screening reportFound: 2021/22 Sickle cell and thalassaemia screening (SCT) screening report
Jul. 24 2023
Source Page: Sickle cell and thalassaemia screening programme: standardsFound: Sickle cell and thalassaemia screening programme: standards
Jul. 14 2023
Source Page: Managing safety incidents in NHS screening programmesFound: within three working days to SQAS and SIT.